An open-label, single-dose, randomized, 3-period, crossover, bioequivalence study between two new formulations of 0.45mg/1.5mg Premarin [conjugated estrogens]/medroxyprogesterone acetate (MPA) compared with a reference formulation of 0.45mg/1.5mg Premarin/MPA (Prempro in healthy postmenopausal women

Trial Profile

An open-label, single-dose, randomized, 3-period, crossover, bioequivalence study between two new formulations of 0.45mg/1.5mg Premarin [conjugated estrogens]/medroxyprogesterone acetate (MPA) compared with a reference formulation of 0.45mg/1.5mg Premarin/MPA (Prempro in healthy postmenopausal women

Completed
Phase of Trial: Phase I

Latest Information Update: 08 Jun 2007

At a glance

  • Drugs Conjugated estrogens/medroxyprogesterone (Primary)
  • Indications Menopausal syndrome
  • Focus Pharmacokinetics
  • Sponsors Wyeth
  • Most Recent Events

    • 08 Jun 2007 Status change from, initiated to completed (according to NCT).
    • 16 Oct 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top